Response of In-vitro Platelet Aggregation Induced by Adenosine Diphosphate and Epinephrine in Stable Angina Pectoris with Essential Hypertension

Hypertension is an independent risk factor for coronary artery di sease (CAD) in both males and females. Platelet activation is seen in the progress of hypertension and CAD. In th is study, the effect of controlled class I-II hypertension on in-vitro platelet aggregation was investigated in patients with stable angina pectoris (SAP). One-lıundre d and three patients were included in the study after canfirmati on of an g ina pectori s c lin ically and angiographically. Patients were divided into two groups: Group I consisted of 45 CAD patients (3 1 male, 14 female, mean age:57±10) with essential hypertension, and 58 normotensive CAD parients (53 male, 5 female, mean age:54±9) made up Group II. Platelet-rich plasma (PRP) samples were prepared from the patients' venous blood taken befo re breakfast at room temperature. PRP was treated with adenesine diphosphate (ADP) and epinephrine and platelet aggregation slopes were obtained by use of turbidometric method of Bohr. These slopes were recorded on special millimetric papers and activation time (second) and activation ratios (amplitude %) of primary and secondary waves were calculated from the slopes. Student's t test was used for statistical analyses. Activation ratios of in-vitro platelet aggregation induced by ADP and epinephrine was significantly increased in group I than group II for borh primary and secondary waves. No difference was found between groups when activation time of primary waves were compared (p>0.05) but activation time of secondary waves were significantly increased in groups I (p<0.05). It was found that use of antihypertensive agents like converting enzyme inhibitors, calcium channel and beta blackers did not cause significant changes in response to platelet aggregation (p>0.05). Hypertensive SAP patients even having been treated by antihypertensive drugs have signi ficantly increased platelet aggregation response w:hen compaı·ed to normotensive SAP patients. But, in vivo prospective studies in wider and more homogeneous hypertensive patients population are necessary to conclude the need for more potent antiaggregant treatment with use of antihypertensive drugs having antiaggregant properties.